Abstract 1562P
Background
Zolbetuximab showed efficacy for gastric cancer with Claudin (CLDN)18.2 expression. CLDN18.2 is reported to be expressed in about 20-50% of gastric cancer, but the definitions varied in previous reports and the relationship with prognosis is controversial. The present study aimed to examine the expression of CLDN18.2 based on SPOTLIGHT/GLOW study and the relationship with prognosis and clinical/molecular characteristics in resected gastric cancer.
Methods
We used a tissue microarray set including gastric cancer samples resected in our institution between July 1989 and September 2009. VENTANA CLDN18 (43-14A) assay was used for immunohistochemistry (IHC) of CLDN18.2. CLDN18.2 expression was judged as positive when ≥75% of the tumor cell membrane was stained in moderate-to-strong intensity by IHC. The Combined Positive Score (CPS) was evaluated using Dako PD-L1 28-8 pharmDx assay.
Results
CLDN18.2 was evaluable in 366 samples and expressed in 139 samples (38%). Clinical data was available in 129 patients (pts) with CLDN18.2+ vs 191 CLDN18.2- pts. Patient characteristics in the CLDN18.2+ group vs the CLDN18.2- group were as follows; median age (range), 64 (27 - 85) vs 66 (35 - 83); gender male 94 (73%) vs 139 (73%); HER2 positive 11 (10%) vs 19 (10%); CPS ≥5, 64 (50%) vs 88 (46%); dMMR, 4 (3.1%) vs 5 (2.6%); Lauren classification diffuse, 71 (55%) vs 107 (56%); pTstage 1/2/3/4, 13/15/17/84 vs 17/34/28/112; pNstage 0/1/2/3, 27/31/32/39 vs 41/39/50/61; pStage I/II/III, 13/36/80 vs 14/68/109; and adjuvant S-1, 43 (33%) vs 54 (28%). Three-year RFS was 56.8% in the CLDN18.2+ group vs 60.3% in the CLDN18.2- group (HR = 1.07 [95% CI 0.77-1.49], p = 0.68). Three-year OS was 66.9% in the CLDN18.2+ group vs 68.7% in the CLDN18.2- group (HR = 1.13 [95% CI 0.80-1.59], p = 0.49).
Conclusions
CLDN18.2 expression was observed in 38% of resected gastric cancer samples, which was consistent with previous reports. CLDN18.2 expression was not related to prognosis and specific relationship was not observed in clinical/molecular characteristics of resected gastric cancer.
Clinical trial identification
Editorial acknowledgement
The Authors would like to thank Charles McKay for English language editing.
Legal entity responsible for the study
M. Furuta.
Funding
Has not received any funding.
Disclosure
M. Furuta: Financial Interests, Personal, Invited Speaker: Eli Lilly, Bristol Myers Squibb, Merck & Co., Inc., Ono Pharamceutical Co. Ltd., , Takeda Pharmaceutical Company Limited. N. Machida: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Ono, Taiho, MSD, Daiichi Sankyo, Yakult, Eli Lilly Japan, Chugai, Astellas, Takeda, Merck biopharma, Nichi-Iko, Nippon-Kayaku; Financial Interests, Institutional, Local PI: Bristol Myers Squibb, Ono, Daiichi Sankyo, Astellas, MSD, Amgen, ALX Oncology, Seagen. J. Furuse: Financial Interests, Personal, Invited Speaker: Ono Pharmaceutical, Bayer, Eisai, Eli Lilly Japan, MSD, Yakult Honsha, Chugai Pharma, Novartis Pharma, AstraZeneca, Pfizer, Takeda, Taiho Pharmaceutical, Sanofi, Mylan EPD, EA Pharma, Kyowa Hakko Kirin, Daiichi Sankyo, Teijin pharma, Servier Japan, Incyte; Financial Interests, Personal, Advisory Board: Fuji film, Mudi Pharma, Onco Therapy Science, Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Chugai Pharma, Astellas, AstraZeneca, Takara bio, Delta-Fly-Pharma, Incyte Japan; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical, MSD, Merck Bio, J-Pharma, Taiho Pharmaceutical, Takeda, Chugai Pharma, AstraZeneca, Yakult Honsha, Eisai, Daiichi Sankyo, Mochida, Sanofi, Sumitomo Dainippon Bayer, Astellas, Incyte Japan; Financial Interests, Personal, Steering Committee Member: Merck Bio, Ono Pharmaceutical, MSD, Taiho Pharmaceutical, Astellas, AstraZeneca, Incyte Japan. All other authors have declared no conflicts of interest.
Resources from the same session
1468P - Patients’ perspective on tolerability of dostarlimab in NSCLC: Patient-reported outcomes from the phase II PERLA trial
Presenter: Martin Reck
Session: Poster session 21
1469P - The role of the CXCL12/CXCR4 pathway in the immunotherapy of non-small cell lung cancer
Presenter: Jacobo Rogado
Session: Poster session 21
1470P - Statin use and overall mortality in patients with advanced non-small cell lung cancer receiving anti-PD(L)1 immunotherapy: A SEER Medicare database analysis
Presenter: Joshua Reuss
Session: Poster session 21
1471P - Immunotherapy prolongs long-term real-world survival compared to chemotherapy for metastatic non-small cell lung cancer: A propensity score-matched analysis
Presenter: Kun Kim
Session: Poster session 21
1472P - Radiotherapy affects immunotherapy efficacy based on tumor mutation status in patients with metastatic NSCLC
Presenter: Shenduo Li
Session: Poster session 21
1473P - Efficacy of anti-PD1/PDL1 antibody monotherapy in patients with advanced non-small cell lung cancer with increased hepcidin expression
Presenter: Masaki Yamamoto
Session: Poster session 21
1474P - Outcome of nivolumab and ipilimumab-based therapy for advanced non-small cell lung cancer with low or negative PD-L1 expression
Presenter: Takafumi Fukui
Session: Poster session 21
1475P - Torque teno virus DNA load as biomarker for tumor response to mono immune checkpoint inhibition in non-small cell lung cancer
Presenter: Benthe Muntinghe
Session: Poster session 21
1476P - Outcomes to first-line pembrolizumab in patients with advanced NSCLC and high PD-L1 expression: A Spanish multicentric study
Presenter: Aida Piedra
Session: Poster session 21
1477P - STK11 mutations predict poor prognosis for advanced NSCLC treated with first-line immunotherapy or chemo-immunotherapy according to KRAS, TP53, KEAP1, and SMARCA4 status
Presenter: Andrea De Giglio
Session: Poster session 21